Clinical experience with CF-FUra.

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Metastatic colorectal cancer (mCRC) remains a significant health challenge.
• Optimizing chemotherapy regimens like leucovorin (CF) and fluorouracil (FUra) is crucial for improving patient outcomes.
• Minimizing toxicity while maximizing efficacy is a key goal in mCRC treatment.

Purpose of the Study:

• To evaluate the toxicity and efficacy of two different administration schedules of CF-FUra in patients with mCRC.
• To assess the correlation between objective responses, disease stabilization, and patient survival.
• To determine the optimal dosing strategy for oral CF with IV FUra in a pre-randomized trial setting.

Main Methods:

• Two clinical trials were conducted using CF-FUra in mCRC patients.
• Trial 1: IV CF with a constant dose of IV FUra (400 mg/m2).
• Trial 2: Oral CF with escalating doses of IV FUra, including folate level monitoring.

Main Results:

• Trial 1 showed objective responses in 36% and disease stabilization in 31%, correlating with prolonged survival (median 8-10 months).
• Toxicity in Trial 1 (diarrhea, weakness) was manageable by dose adjustment.
• Trial 2 reported a 35% response rate and 35% stabilization, with a median survival of 14 months and 12-month survival of 56%, despite various toxicities.

Conclusions:

• CF-FUra demonstrates objective responses and disease stabilization in mCRC patients, correlating with improved survival.
• Both IV and oral CF combined with FUra show potential efficacy, with manageable toxicity profiles.
• Further randomized trials are warranted to confirm the superiority of specific CF-FUra regimens in mCRC treatment.